NCT03618550

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 257 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

Conditions

• Hodgkin Lymphoma
• Relapsed or Refractory Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	pembrolizumab	Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
DRUG	gemcitabine	1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
DRUG	vinorelbine	20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
DRUG	liposomal doxorubicin	15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
PROCEDURE	Stem cell mobilization and collection	Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.

Timeline

• Start date: 2018-08-01
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2018-08-07
• Last updated: 2026-04-16

Locations

10 sites across 1 country: United States

Regulatory

• FDA-regulated drug study